Pertactin-negative variants of Bordetella pertussis in New York State: A retrospective analysis, 2004-2013

Molecular and Cellular Probes

Volumn 28, Issue 4, 2014, Pages 138-140

  Quinlan, Tammy ^a   Musser, Kimberlee A ^a   Currenti, Salvatore A ^b   Zansky, Shelley M ^b   Halse, Tanya A ^a  

^a WADSWORTH CENTER   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Acellular vaccine; Bordetella pertussis; Pertactin negative variants

Indexed keywords

PERTACTIN; PERTUSSIS VACCINE; BACTERIAL DNA; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CHILD; CLINICAL ARTICLE; GENE INSERTION; GENE MUTATION; HUMAN; INFANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEQUENCE ANALYSIS; STOP CODON; UNITED STATES; VACCINATION; CLASSIFICATION; DNA SEQUENCE; GENETIC VARIABILITY; GENETICS; METABOLISM; MICROBIOLOGY; MUTATION; WHOOPING COUGH; YOUNG ADULT;

BORDETELLA PERTUSSIS;

ADOLESCENT; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CHILD, PRESCHOOL; DNA, BACTERIAL; GENETIC VARIATION; HUMANS; INFANT; MUTATION; NEW YORK; PERTUSSIS VACCINE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH; YOUNG ADULT;

EID: 84901276122     PISSN: 08908508     EISSN: 10961194     Source Type: Journal    
DOI: 10.1016/j.mcp.2013.12.003     Document Type: Article

References (15)

1. Barkoff A.-M., Mertsola J., Guillot S., Guiso N., Berbers G., He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol 2012, 19:1703-1704.
2. http://www.health.ny.gov/statistics/diseases/communicable/2010/cases/4.htm.
3. http://www.health.ny.gov/statistics/diseases/communicable/2011/cases/5.htm.
4. http://www.health.ny.gov/statistics/diseases/communicable/2012/cases/4.htm.
5. Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. NEngl J Med 2012, 367:1012-1019.
6. Queenan A.M., Cassiday P.K., Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. NEngl J Med 2013, 368:583-584.
7. Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G.J., Gaastra W., Willems R.J.L. Polymorphism in the Bordetella pertussis virulence factors P.69/Pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998, 66:670-675.
8. Hegerle N., Paris A.S., Brun D., Dore G., Njamkepo E., Guillot S., et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect 2012, 18:E340-E346.
9. Mooi F.R., H H., Wirsing von Konig C.H., Hoet B., Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis 2000, 19:174-181.
10. Otsuka N., Han H.-J., Toyoizumi-Ajisaka H., Nakamura Y., Arakawa Y., Shibayama K., et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS ONE 2012, 7:e31985.
11. Fry N.K., Neal S., Harrison T.G., Miller E., Matthews R., George R.C. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun 2001, 69:5520-5528.
12. Pawloski L.C., Queenan A.M., Cassiday P.K., Lynch A.S., Harrison M., Shang W., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol 2013.
13. Bodilis H., Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis 2013, 19:471-474.
14. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6246md.htm?s_cid=mm6246md_w%20-%20tab2.
15. Centers for Disease Control Summary of notifiable diseases, United States, 2011. MMWR 2013, 60:1-117.